Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis

OBJECTIVE: This study aimed to review effectiveness studies comparing two biological anti-tumour necrosis factor agents, adalimumab (ADA) and infliximab (IFX), in the management of autoimmune uveitis. METHODS: A systematic search was conducted across PubMed, Scopus, Web of Science and Google Scholar...

Descripción completa

Detalles Bibliográficos
Autores principales: Mase, Oliver, Qasem, Mustafa, Beare, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Uveitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277136/
https://www.ncbi.nlm.nih.gov/pubmed/37493653
http://dx.doi.org/10.1136/bmjophth-2023-001303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277136/
https://www.ncbi.nlm.nih.gov/pubmed/37493653
http://dx.doi.org/10.1136/bmjophth-2023-001303

Ejemplares similares